抗凝治疗的重症COVID-19患者静脉血栓栓塞事件高发
该回顾性研究在2个法国ICU对26例重症COVID-19患者早期行完整双功超声筛查静脉血栓栓塞(VTE),其中8例(31%)接受预防性抗凝、18例(69%)接受治疗性抗凝。总体VTE发生率为69%,预防性抗凝组VTE比例显著高于治疗性抗凝组(100% vs 56%,P=.03),治疗性抗凝组仍有56%发生VTE并发现6例肺栓塞。
要点
- 重症COVID-19抗凝患者总体VTE发生率高达69%。
- 预防性抗凝组VTE比例100%,显著高于治疗性抗凝组56%。
- 治疗性抗凝组仍高发血栓事件,需考虑系统筛查VTE。
核心结论
- 重症ICU COVID-19患者即使接受抗凝治疗,VTE发生率仍很高,建议考虑系统筛查VTE并早期治疗性抗凝。
研究设计与样本
- 回顾性研究,在2个法国ICU纳入2020年3月19日至4月11日连续26例重症COVID-19患者,早期行完整双功超声筛查VTE。
- 抗凝剂量由主治医师根据个体血栓风险决定,分为预防性抗凝组8例(31%)和治疗性抗凝组18例(69%)。
主要发现
- 总体VTE发生率为69%。
- 预防性抗凝组VTE比例为100%,治疗性抗凝组为56%,两组差异有统计学意义(P=.03)。
- 治疗性抗凝组中56%发生VTE,并发现6例肺栓塞。
关键数值与推荐
- 完整双功超声从大腿至踝部在选定部位行多普勒波形和图像检查,于ICU住院早期进行。
- 对持续低氧血症或继发恶化的患者系统排查肺栓塞。
临床怎么用
- 对重症ICU COVID-19患者应考虑系统筛查VTE。
- 结果提示可考虑早期治疗性抗凝,但需结合个体血栓风险决定。
局限性
- 回顾性研究,样本量小(26例),来自2个法国ICU。
- 抗凝剂量非随机分配,由主治医师根据个体风险决定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe COVID-19 patients. OBJECTIVES: Systematic assessment of venous thromboembolism (VTE) using complete duplex ultrasound (CDU) in anticoagulated COVID-19 patients. PATIENTS AND METHODS: We performed a retrospective study in 2 French intensive care units (ICU) where CDU is performed as a standard of care. A CDU from thigh to ankle at selected sites with Doppler waveforms and images was performed early during ICU stay in patients admitted with COVID-19. Anticoagulation dose was left to the discretion of the treating physician based on the individual risk of thrombosis. Patients were classified as treated with prophylactic anticoagulation or therapeutic anticoagulation. Pulmonary embolism was systematically searched in patients with persistent hypoxemia or secondary deterioration. RESULTS: From March 19 to April 11, 2020, 26 consecutive patients with severe COVID-19 were screened for VTE. Eight patients (31%) were treated with prophylactic anticoagulation, whereas 18 patients (69%) were treated with therapeutic anticoagulation. The overall rate of VTE in patients was 69%. The proportion of VTE was significantly higher in patients treated with prophylactic anticoagulation when compared with the other group (100% vs 56%, respectively, P = .03). Surprisingly, we found a high rate of thromboembolic events in COVID-19 patients treated with therapeutic anticoagulation, with 56% of VTE and 6 pulmonary embolisms. CONCLUSION: Our results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID-19 patients.
引用
- Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020. PMID: 32320517. doi:10.1111/jth.14869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。